Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Actinobac’s drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera® are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis. For the millions of patients who suffer from blood cancers, autoimmune diseases, and inflammatory conditions, Actinobac offers new hope because their products specifically target and eliminate the diseased cells. This means greater benefit with fewer side effects. Actinobac’s goal is to not just change lives, but also save them.
Year Founded: 2009
Key Executive:
• Dr. Scott Kachlany, Founder and Chief Scientific Officer
Location: Kendall Park, NJ
Website: http://www.actinobac.com/
Company Status: Private
Year Invested: 2017
Investment Status: Current
Board Member:
Alex Andrianopoulos
The approval clears the way for Kachlany’s company, Actinobac Biomed, to initiate a phase I clinical...
We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made...
Copyright © 2024 Kairos Venture Investments, LLC.
Year Founded: 2009
Key Executive:
• Dr. Scott Kachlany, Founder and Chief Scientific Officer
Location: Kendall Park, NJ
Website: http://www.actinobac.com/
Company Status: Private
Year Invested: 2017
Investment Status: Current
Board Member:
Alex Andrianopoulos
The approval clears the way for Kachlany’s company, Actinobac Biomed, to initiate a phase I clinical...
We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made...
Copyright © 2024 Kairos Venture Investments, LLC.
Location: United States, New Jersey, South Brunswick
Total raised: $5.41M
Investors 1
| Date | Name | Website |
| - | Kairos Ven... | kairosvent... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.07.2017 | - | $4.4M | - |
| 27.10.2014 | - | $905K | - |
| 23.02.2013 | Seed | $100K | - |
Mentions in press and media 4
| Date | Title | Description |
| 14.07.2017 | Actinobac Biomed Receives Up To $4.4M Investment | Actinobac Biomed Inc., a New Brunswick, N.J.-based biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV, received an investment of up to $4.4m from Ka... |
| 27.10.2014 | Actinobac Biomed Receives $905K STTR Phase II Award | Actinobac Biomed Inc., a New Brunswick, N.J.-based pharma companies, received a $905k Small Business Technology Transfer Grant (STTR) Phase II Award from the National Institutes of Health/ National Cancer Institute. The company will use the... |
| 23.02.2013 | Actinobac Biomed Raises $100K in Seed Financing | Actinobac Biomed Inc., a North Brunswick, NJ-based developer of pharmaceutical technologies, raised $100k in seed financing. Foundation Venture Capital Group (FVCG), an affiliate of New Jersey Health Foundation, made a follow on investment.... |
| 22.02.2013 | Actinobac Biomed Secures $100K | NEW BRUNSWICK, NJ, Actinobac Biomed, Inc., has received a commitment for a second investment of $100,000 from Foundation Venture Capital Group (FVCG). >> Click here for more funding data on Actinobac Biomed >> To export Acti... |